Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare fax automation AI extracting referral and authorization data into EHR workflows; eliminating manual fax processing for medical practices where 80% of communications are still faxed.
Tennr is an AI-powered healthcare operations platform that automates fax-based administrative workflows for healthcare providers — extracting data from incoming faxes (referrals, prior authorizations, lab results, patient records) and automatically routing, categorizing, and populating EHR workflows to eliminate the manual data entry that consumes significant administrative staff time at medical practices and health systems. Founded in 2021 and headquartered in New York, Tennr has raised approximately $18 million targeting the persistent problem of healthcare fax volume, as US healthcare still transmits approximately 80% of inter-provider communications via fax.\n\nTennr's AI system reads incoming fax documents, identifies the document type (referral, authorization request, clinical note), extracts key clinical data (patient name, DOB, diagnosis codes, requested procedures), and automatically creates the corresponding workflows in the practice management or EHR system — eliminating the need for front desk staff to manually read faxes, type data into multiple systems, and track follow-up actions. The platform integrates with major EHR systems (Epic, Athenahealth, eClinicalWorks) to push extracted data directly into the right fields.\n\nIn 2025, Tennr operates in the healthcare administrative AI market alongside Thoughtful AI (healthcare billing automation), Olive AI (now restructured), and general RPA platforms that healthcare organizations adapt for administrative workflows. The healthcare fax automation market is significant — large specialty practices can receive thousands of faxes daily, with each requiring manual processing. Tennr's AI-native approach for healthcare document understanding (trained specifically on medical fax content) differentiates it from generic document AI. The 2025 strategy focuses on expanding to more specialty practices, deepening integrations with more EHR platforms, and adding prior authorization automation as a high-value workflow.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.